Dr. Reddy’s Laboratories’ American depositary shares (RDY) climbed after news that India’s drug regulator granted final approval for the company to manufacture and sell generic oral semaglutide tablets in three strengths—3 mg, 7 mg and 14 mg—mirroring the dose lineup of Novo Nordisk’s Rybelsus franchise. (m.economictimes.com)

Oral semaglutide is one of the most commercially important products in metabolic disease, and an approved generic version meaningfully expands Dr. Reddy’s addressable market in India and potentially other geographies over time. Investors are treating the approval as a catalyst that can offset pricing pressure in mature generic categories and add a higher-profile growth driver tied to GLP-1 demand. (m.economictimes.com)

A central uncertainty is ongoing litigation tied to Novo Nordisk’s oral semaglutide patent claims, which focus on the SNAC excipient concentration used to enable absorption in tablet form. Court filings describe Dr. Reddy’s position that its formulation uses an SNAC amount outside the patented range, but the dispute could still lead to restrictions, delays, or altered launch plans depending on court outcomes. (indiankanoon.org)

Traders will focus on (1) any announcement on launch timing and pricing strategy for the tablets in India, (2) near-term court developments that could affect commercial rollout, and (3) management commentary on how oral semaglutide fits into its broader GLP-1 pipeline and export/filing strategy. (moneycontrol.com)